Just Group: Deutsche Bank initiates at hold with a target price of 170p.
Clinical-stage biopharmaceutical company Verona Pharma updated the market on its operations on Tuesday, confirming that in the quarter to 31 March it successfully completed two further clinical trials with nebulized RPL554 ahead of schedule.
Kenneth Newman, chief medical officer of clinical-stage biopharmaceutical company Verona Pharma, will stand down from his position on 30 April in order to pursue "other opportunities".
Top-line data from Verona Pharma's phase 2b clinical study of chronic obstructive pulmonary disease treatment showed a large and sustained improvement in lung function, showing the drug holds potential to be a new complementary treatment.
Verona Pharma's shares leapt after it announced on Friday that it had obtained "favourable" top line data from its most recent clinical trials for a treatment of cystic fibrosis (CF).
Biopharmaceutical company Verona Pharma expects to receive results from ongoing clinical trials earlier than originally anticipated.
Clinical-stage biopharmaceutical company Verona Pharma announced top-line results from its clinical pharmacokinetic (PK) trial in the United States on Wednesday, which it said demonstrated that inhaled RPL554 is an "appropriate form of administration" for patients with chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, posted an update on clinical developments along with its interim results for the six months ended June 30.
Clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, Verona Pharma, announced on Tuesday that the first patient had been enrolled and dosed in a Phase 2a clinical study to evaluate its product candidate, RPL554, as a treatment for cystic fibrosis.
Clinical-stage biopharmaceutical company Verona Pharma announced its audited results for the year to 31 December on Monday, a period in which it raised gross proceeds of £44.7m from a placing of 1.56bn units at a price of 2.873p per unit, with each unit comprising one new ordinary share and one warrant to purchase 0.4 of an ordinary share.
Verona Pharma's shares are up more than 1% after it confirmed the first patient had been dosed in its Phase 2a clinical trial evaluating RPL554 in the treatment of chronic obstructive pulmonary disease (COPD).
AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug.
Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554".
Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed.
Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling.
Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD).
Shares in Verona Pharma rallied after it announced positive headline data from the third and final part of a clinical study on its RPL554 drug for the treatment of chronic obstructive pulmonary disease.
Shares in Verona Pharma plunged over 12% early on Tuesday, after the pharmaceutical company posted a wider interim pre-tax loss.
AIM-listed drug developer Verona Pharma has carried out a second listing in Germany.
Verona Pharma posted a widened pre-tax loss for 2014 in the run up to its lead compound's commercial development.